Your session is about to expire
← Back to Search
IVLP with Oxaliplatin for Colorectal Cancer Spread to Lungs
Study Summary
This trial is testing a new way to deliver chemotherapy to the lungs during surgery, potentially avoiding side effects to other organs. Participants will get oxaliplatin and be monitored for safety, with doses increased until severe but temporary side effects are seen.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 4 trial • 128 Patients • NCT01588990Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am allergic or cannot take cefazolin or methylprednisolone but can join without taking them.I am either 71 years old or older, or younger than 18.I have had serious lung disease or inflammation.I have received over 1000 mg of oxaliplatin.I have been diagnosed with colorectal cancer.I am able to care for myself and move around.I am 70 years old or younger.My cancer has spread to both lungs.My cancer is mainly in my lungs, but may have spread to my liver where it can still be treated.
- Group 1: IVLP in single lung
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any criteria that would disqualify individuals from taking part in this experiment?
"This clinical study is accepting approximately 10 participants with a diagnosis of colorectal cancer, aged between 18 and 70."
What potential risks do patients face when undergoing Intravenous Lung Lavage Procedure (IVLP) on a single lung?
"Our experts at Power rated the safety of IVLP in single lung as a 1 due to its status as an early-stage trial, which suggests there is limited supporting evidence for efficacy and security."
Does this research protocol accept individuals aged fifty or above?
"As detailed in the inclusion criteria, only individuals aged 18 to 70 can join this clinical trial. In comparison, there are 67 trials available for people under 18 and 1650 studies open to those over 65."
How many participants are involved in this experiment?
"Affirmative. According to the information posted on clinicaltrials.gov, this trial is actively recruiting subjects and was initially published in February of 2023 with a subsequent update occurring in March 2021. It requires 10 participants from one medical site for completion."
Are there any openings available in this clinical trial?
"Based on clinicallytrials.gov, the research team is actively searching for participants to join this trial which was first announced in February 6th 2023 and recently revised at March 21st 2023."
Share this study with friends
Copy Link
Messenger